Search
Human botulinum neurotoxin A/B immune globulin
go.drugbank.com/drugs/DB14115ApprovedInfant botulism is a rare infectious disease occurring in infants in which _Clostridium botulinum_ colonize the large intestine and being to produce botulinum neurotoxin directly in the gut. … [L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003[L39814] and has since been used to treat more than 2100 cases of infant botulism.
Synonyms: Botulism immune globulin IV human, Botulism immune globulin intravenous (human) (BIG-IV)Rusfertide
go.drugbank.com/drugs/DB17724ApprovedInvestigationalRusfertide is a hepcidin mimetic used to treat erythrocytosis in adults with polycythemia vera. … [L64098] The FDA approved rusfertide on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer.
Olodaterol
go.drugbank.com/drugs/DB09080ApprovedInvestigationalSingle doses of olodaterol have been shown to improve forced expiratory volume in 1 sec (FEV1) for 24 h in patients with COPD, allowing once daily dosing. … Despite similarities in symptoms, olodaterol is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma.
Magnesium gluconate
go.drugbank.com/drugs/DB13749ApprovedWithdrawnMagnesium is ubiquitous in the human body, and is naturally present in many foods, added to other food products, available as a dietary supplement and used as an ingredient in some medicines (such as antacids … In addition, it has been studied for its effects on premature uterine contractions [A32808].
Maftivimab
go.drugbank.com/drugs/DB15899ApprovedInvestigational(i.e. through Fc-mediated immune effector function) antibody effects to play a role in combatting EBOV infection. … [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.
Deoxycholic acid
go.drugbank.com/drugs/DB03619ApprovedInvestigationalDeoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that … In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity.
Umeclidinium
go.drugbank.com/drugs/DB09076ApprovedInvestigationalANORO ELLIPTA was approved in December 2013 while TRELEGY ELLIPTA was approved in September 2017.[L46881,L46886] … [A7719] However, even though umeclidinium monotherapy is well-tolerated for up to 14 days, it is more likely to be used in combination therapy, as the international Gold Initiative for Chronic Obstructive
Crinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigational[A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993] … [L51973] When administered alongside glucocorticoid replacement in patients with CAH it allows for the use of lower, physiological doses for glucocorticoid replacement, thereby reducing the risks associated
Trofinetide
go.drugbank.com/drugs/DB06045Approved[A258453] Trofinetide is marketed as DAYBUE and DAYBUE STIX in the United States, as DAYBUE in Canada, and as DAYBU in the European Union. … , making trofinetide the first and only treatment approved for Rett syndrome in the European Union.
Marnetegragene autotemcel
go.drugbank.com/drugs/DB17595ApprovedSevere leukocyte adhesion deficiency-I (LAD-I) is a genetic disorder leading to frequent life-threatening infections and high fatality risks among affected pediatric patients. … [L56115, L56116] Marnetegragene autotemcel is indicated for pediatric patients with severe LAD-I lacking an available HLA-matched sibling donor.[L56115]